Safety and Performance of Princess® VOLUME for the Treatment of Facial Lipoatrophy, Asymmetry or Scars — FLASH2

Facial Lipoatrophy Clinical Trial

Official title:
A Prospective, Open-label, Non-comparative, Multicentre, Post-market Clinical Follow-up Study of the Princess® VOLUME Performance and Safety for Correction of Facial Lipoatrophy, Morphological Asymmetry of the Face, or Debilitating Scars

Status Completed

Clinical Trial Summary

In this study, eligible patients with the medical indications (facial lipoatrophy, morphological asymmetry of the face, or debilitating scars) will be treated with Princess® VOLUME, and then will return for follow-up assessments 2, 4, 24, and 36 weeks after the treatment. A touch-up treatment may be done 2 weeks after the treatment if deemed appropriate by the Investigator.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Debilitating Scars
Facial Lipoatrophy
Facies
Lipodystrophy
Morphological Asymmetry of the Face

Clinical Trial Details

NCT number	NCT03050749
Study type	Interventional
Source	Croma-Pharma GmbH
Contact
Status	Completed
Phase	N/A
Start date	November 20, 2016
Completion date	March 6, 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00360932` - Facial Lipoatrophy Correction Experience With SCULPTRA ("FACES" Study)
Completed	`NCT03050723` - Safety and Performance of Princess® FILLER for the Treatment of Facial Lipoatrophy, Asymmetry or Scars	N/A
Completed	`NCT00333684` - Safety, Efficacy and Psychological Effects of Treating Antiretroviral Drug-Induced Facial Lipoatrophy With Bio-Alcamid	Phase 2